CLARIVATE PLC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $CLVT in the last 7 days.
Cornick Kenneth L. purchased 900,000 indirectly-held shares of CLARIVATE PLC (CLVT) at an average of $1.86 ($1.85–$1.86, $1.67M total) across 2 trades over 2026-08-06 to 2026-08-07.
PR Newswire compiled 13 July press releases, including Lilly’s Phase 3 retatrutide results, Kroger’s agreement to acquire Giant Eagle, Clarivate’s sale of its Life Sciences and Healthcare segment for $600 million, BOXABL’s business combination valuing it at $3.5 billion, and Garmin’s LiveScope 2 sonar launch. It also lists other product and corporate updates.
Clarivate Plc (NYSE:CLVT) said it expanded agentic AI capabilities across its Cortellis life sciences portfolio. The company claims the updates embed AI into existing workflows to speed drug discovery decisions, improve safety assessment via multi-agent intelligence, and accelerate competitive and portfolio analysis. Clarivate said the goal is reducing manual effort and improving decision making across the R&D lifecycle.
Recent CLVT coverage spans earnings, insider activity and financial news.
In the last 30 days, CLVT insiders filed 5 SEC Form 4 transactions — 2 purchases ($1.7M) and 3 sales ($4.8M). The most active reporter was Snyder Andrew Miles with 3 filings.
This is an insider open-market purchase, which can be read as modest bullish signaling, but it is not a fundamental catalyst like earnings or guidance.
Segment divestiture can refocus the portfolio and affect earnings mix, leverage, and capital allocation.
This is a product and platform expansion announcement that could support incremental demand for Clarivate’s life-sciences workflow offerings, but it lacks financial guidance or quantified traction.
This is an insider sale under a Form 4, not a company fundamental update. It may modestly affect near-term sentiment but is unlikely to change intrinsic valuation by itself.
The article frames the CFO promotion as a continuity and capital-discipline signal, but it provides no new financial guidance, numbers, or deal terms.
alphai scores every news story that mentions CLVT with an AI model for sentiment and relevance, and aggregates insider trades from CLARIVATE PLC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Cornick Kenneth L. purchased 900,000 indirectly-held shares of CLARIVATE PLC (CLVT) at an average of $1.86 ($1.85–$1.86, $1.67M total) across 2 trades over 2026-08-06 to 2026-08-07.
1 min readPR Newswire compiled 13 July press releases, including Lilly’s Phase 3 retatrutide results, Kroger’s agreement to acquire Giant Eagle, Clarivate’s sale of its Life Sciences and Healthcare segment for $600 million, BOXABL’s business combination valuing it at $3.5 billion, and Garmin’s LiveScope 2 sonar launch. It also lists other product and corporate updates.
7 min readClarivate Plc (NYSE:CLVT) said it expanded agentic AI capabilities across its Cortellis life sciences portfolio. The company claims the updates embed AI into existing workflows to speed drug discovery decisions, improve safety assessment via multi-agent intelligence, and accelerate competitive and portfolio analysis. Clarivate said the goal is reducing manual effort and improving decision making across the R&D lifecycle.
3 min readSnyder Andrew Miles sold 2,489,618 indirectly-held shares of CLARIVATE PLC (CLVT) at $1.94 ($4.83M total) across 3 trades on 2026-08-03.
2 min readSimply Wall St reports Clarivate Plc (CLVT) appointed Michael Easton as CFO and Executive Vice President effective Aug. 8, 2026, after Jonathan Collins’ departure. Easton previously served as Chief Accounting Officer overseeing controllership, reporting, treasury and FP&A. The article links the change to Clarivate’s capital discipline and cites forecasts of $1.9B revenue and $142.7M earnings by 2029.
5 min readClarivate Plc (Q2 2026) discussed its Value Creation Plan to shift from transactional to recurring subscription revenue. It plans to divest the Life Sciences & Healthcare segment by year-end 2026, targeting about 92% recurring revenue pro forma. Management cited a $269m non-cash impairment, $70m one-time costs, and expects low-end FCF due to transaction and restructuring costs.
6 min readClarivate Plc reported a tranche update on its equity buyback plan announced Dec. 16, 2024. From Apr. 1, 2026 to Jun. 30, 2026 it repurchased 0 shares for $0 million. Cumulatively it has bought back 63,042,889 shares, or 9.41%, for $242.63 million.
2 min readCLARIVATE PLC (CLVT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Clarivate Appoints Michael Easton as Chief Financial Officer Experienced Clarivate leader brings more than 25 Years of financial and operational expertise LONDON, July 29, 2026: Clarivate Plc (NYSE: CLVT) ("Clarivate" or the "Company"), a leading global provider of transformative
2 min readClarivate (NYSE:CLVT) discussed its Q2 outlook on an earnings call, focusing on AI initiatives tied to its Model Context Protocol (MCP) and embedding proprietary data into customer AI environments. It cited 19 product initiatives and named Web of Science Research Intelligence, Harmaspecto and IPOne as potential revenue streams. Transactional revenue faced life sciences pressure, though the sale was agreed after quarter-end; full-year guidance assumes a slight YoY decline.
6 min readClarivate Plc (CLVT) reported Q2 2026 results for the quarter ended June 30, 2026. It had 639.7M ordinary shares. Total assets were $10,486.1M and equity $4,537.5M. Net loss was $268.6M, or EPS (basic) $(0.42). The company is executing a Life Sciences and Healthcare divestiture and highlighted restructuring costs and high interest expense.
6 min read
